Variable | Â |
---|---|
Demographic data | |
 Female, n (%) | 148 (38) |
 Age, years | 67 ± 14 |
 Height, cm | 161 ± 11 |
 Body weight, kg | 57 ± 15 |
 Body mass index, kg/m2 | 22 ± 4 |
LVEF, % | 39 ± 14 |
NYHA class II/III/IV, n | 291/67/33 |
Underlying heart disease | |
 Coronary artery disease, n (%) | 59 (15) |
 Nonischaemic cardiomyopathies, n (%) | 109 (28) |
 Valvular disease, n (%) | 57 (15) |
 Hypertensive heart disease, n (%) | 27 (7) |
 Congenital heart disease, n (%) | 26 (7) |
 Others, n (%) | 113 (29) |
Atrial fibrillation | |
 Permanent/persistent, n (%) | 312 (80) |
 Paroxysmal, n (%) | 76 (20) |
ICD/pacemaker, n (%) | 53 (14) |
Clinical laboratory data | |
 Serum creatinine, mg/dL | 0.94 [0.75–1.15] |
 CLCR, mL/min | 56.5 [40.7–75.6] |
 eGFR, mL/min/1.73m2 | 58.1 [44.7–71.0] |
Daily dose of digoxin | |
 0.25 mg, n (%) | 51 (13) |
 0.125 mg, n (%) | 287 (73) |
 0.0625 mg, n (%) | 39 (10) |
 Other doses, n (%) | 14 (4) |
Duration of digoxin treatment, days | 350 [60–1340] |
Concurrent medications of interest | |
 Amiodarone, n (%) | 63 (16) |
 Diltiazem, n (%) | 33 (8) |
 Verapamil, n (%) | 23 (6) |